Evaluation of a Digital Treatment Tool in Combination With Obesity Medications
Sponsor: Karolinska Institutet
Trial Details
| Condition | Childhood Obesity, Treatment Adherence |
| Intervention | Digi-physical treatment tool, Evira; Obesity medication with liraglutide or semaglutide |
| Phase | NA |
| Status | Recruiting |
| Participants | 40 |
| Est. Completion | 1 Apr 2027 |
| Last Updated | 5 May 2026 |
Primary Outcome
Change in BMI SDS
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Patients offered liraglutide or semaglutide in accordance with the clinic's routines. * Aged 12-17 years at the time of inclusion. * The family agrees to participate in a clinical study. Exclusion Criteria: * Endocrine disorders other than well-controlled hypothyroidism. * Severe neuropsychiatric disorders that may affect adherence to the study. * Eating disorder requiring treatment within the last six months before inclusion or observed during screening prior to inclusion. * Somatic conditions that may complicate the evaluation of treatment outcomes, such as patients on irregular oral corticosteroid treatment. * Hypothalamic or monogenic obesity, and genetic syndromes such as Down syndrome. * Patients deemed unsuitable for participation by the responsible physician.
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service